Robert Alan Baiocchi MD PhD
Hematologic Oncology
Professor, Internal Medicine, Ohio State University College of Medicine
Join to view full profile
460 W 10th Ave5th FloorColumbus, OH 43210
Phone+1 614-293-3196
Fax+1 614-293-4812
Dr. Baiocchi is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Ohio State University HospitalFellowship, Hematology and Medical Oncology, 2001 - 2004- Ohio State University HospitalResidency, Internal Medicine, 1999 - 2001
- Ohio State University College of MedicineClass of 1999
SUNY BUffaloMD, medicine, 1995 - 1997- State University of New York CollegePh.D, Physiology, 1994
Certifications & Licensure
OH State Medical License 2000 - 2027
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2012, 2014, 2016-2017
- Early Career Innovator of the Year Nomination The Ohio State University, 2012
Clinical Trials
- Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma
- Lenalidomide in Treating Patients With AIDS-Associated Kaposi's Sarcoma Start of enrollment: 2010 Aug 27
- Autologous Transplant in HIV Patients (BMT CTN 0803)
Publications & Presentations
PubMed
- Navigating physician-scientist careers: insights from American Board of Internal Medicine Research Pathway graduates.Emily J Gallagher, Barbara I Kazmierczak, Michael Kisielewski, Nathan Schoettler, Clifford J Steer
JCI Insight. 2026-08-24 - Identifying the angiogenic receptor expression in mantle cell lymphoma patients and murine models.Satishkumar Singh, Yuanfeng Wang, Anuvrat Sircar, Udita Jindal, Noura Srour
Biomarker Research. 2026-07-24 - BRG1-mediated suppression of ferroptosis underlies BTK inhibitor resistance.Soo-Yeon Hwang, Xiangao Huang, Helgi Nikolli, Belem Yoval-Sánchez, Sieun Yang
Nature Communications. 2026-07-02
Journal Articles
- ROR1 targeted delivery of OSU-2S, a non-immunosuppressive FTY720 derivative exerts potent cytotoxicity in mantle cell lymphoma in-vitro and in-vivoMani R, Chiang CL, Frissora FW, Yan R, Mo X, Baskar S, Rader C, Phelps MA, Chen CS, Lee RJ, Byrd JC, Baiocchi R, Lee LJ, Muthusamy N, Exp Hematol, 1/1/2015
- AIDS Malignancy Consortium AMC 048: modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphomaNoy A, Lee JY, Cesarman E, Ambinder R, Baiocchi R, Reid E, Ratner L, Wagner-Johnston N, Kaplan L, Blood, 1/1/2015
- The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and ref...Christian BA, Poi M, Jones JA, Porcu P, Maddocks K, Flynn JM, Benson DM Jr, Phelps MA, Wei L, Byrd JC, Wegener WA, Goldenberg DM, Baiocchi RA, Blum KA, Br J Haematol, 1/1/2015
Books/Book Chapters
Abstracts/Posters
- Brentuximab Vedotin (BV) and Lenalidomide (Len) in Relapsed and Refractory (r/r) Cutaneous (CTCL) and Peripheral (PTCL) T-Cell Lymphomas; A Planned Interim Analysis of...Robert A Baiocchi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- PRMT5 Inhibition Drives Therapeutic Vulnerability to BCL-2 Inhibition with Venetoclax and Provides Rationale for Combination Therapy in Mantle Cell LymphomaRobert A Baiocchi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Targeting Hypersumoylation in Mantle Cell LymphomaRobert A Baiocchi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- PRMT5 Is Upregulated in Activated T Cells and Is a Novel Therapeutic Target for Acute Gvhd2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Post graduate career options for the physician scientistChicago, IL - 1/26/2015
- Targeting Histone Methyltransferases and Demethylases trackBoston, MA - 1/24/2015
Press Mentions
OSU Doctor Looks into Viruses That May Lead to CancerMay 11th, 2019
Atara Biotherapeutics Announces Two Presentations at 59th American Society of Hematology Annual Meeting, Including Positive Interim Results from a Multicenter Expanded Access Study of ATA129 for Patients with Epstein-Barr Virus (EBV)-Associated CancersNovember 1st, 2017
Possible New Target for Future Brain Cancer DrugsFebruary 27th, 2014
Grant Support
- The Ohio State University Research in Residency Physician Scientist InitiativeOHIO STATE UNIVERSITY2024–2029
- Development Of Novel Compounds To Inhibit PRMT5 Enzyme In High Grade AstrocytomasNational Institute Of Neurological Disorders And Stroke2010–2011
- Development Of Vaccine Strategies To Prevent EBV+ Lymphoma In Patients With HIVNational Cancer Institute2009–2010
- Ptld: Cytokine Production And Gene PolymorphismsNational Cancer Institute2005
- Biologic Modifier Therapies In AIDS MalignanciesNational Cancer Institute2003
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
